title: [Developments in drugs and populations at risk].
abstract: No therapeutic effectiveness without unwanted side-effects. This well-known problem persists in spite of modern methods for development of new drugs. Therefore no drug-therapy should be initiated without exact risk-benefit-analysis. Especially for drugs introduced recently, effectiveness is better defined than tolerance. In the USA annual costs of 3 million $ due to drug-side-effects have been estimated, indicating an immense socio-economic relevance next to medical or personal aspects. Therefore effective means and strategies should be accepted and used: General reduction of drug consumption, avoidance of polytherapy with respect to known and unknown interaction of side-effects, strict observation of proper indications, amelioration of surveillance for recently introduced drugs and better consideration of special populations at risk.
authors.forename: P H
authors.initials: PH
authors.lastname: Hinderling
mesh_terms: D003257:Consumer Product Safety; D004339:Drug Compounding; D004342:Drug Hypersensitivity; D004347:Drug Interactions; D004358:Drug Therapy / Q000592:standards; D004359:Drug Therapy, Combination; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans
vernacular_title: Arzneimittelentwicklung und Risikopopulationen.